X4 Pharmaceuticals (XFOR) Cash from Financing Activities (2017 - 2025)

X4 Pharmaceuticals' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $146.1 million for Q4 2025.

• Quarterly Cash from Financing Activities rose 108116.3% year-over-year to $146.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $238.6 million (up 1075.85% YoY) and the FY2025 annual result came in at $238.6 million, up 1075.85% from the prior year.
• Cash from Financing Activities was $146.1 million for Q4 2025 at X4 Pharmaceuticals, up from $86.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $146.1 million in Q4 2025 and bottomed at -$4.4 million in Q3 2021.
• A 5-year average of $31.7 million and a median of $20.2 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities tumbled 1521.54% — and 2025, when it jumped 108116.3%.
• X4 Pharmaceuticals' Cash from Financing Activities stood at $24.6 million in 2021, then surged by 146.82% to $60.6 million in 2022, then slumped by 99.84% to $97000.0 in 2023, then jumped by 39.18% to $135000.0 in 2024, then soared by 108116.3% to $146.1 million in 2025.
• Business Quant data shows XFOR's Cash from Financing Activities at $146.1 million in Q4 2025, $86.9 million in Q3 2025, and $5.6 million in Q2 2025.